Abstract
Immunotherapies are beginning to revolutionise treatment paradigms in oncology with monoclonal antibodies (mAb) targeting T-cell co-inhibitory (e.g. PD-1/PD-L1) and co-stimulatory pathways (e.g. CTLA-4/CD28) demonstrating clinical utility. Some clinical studies demonstrate that responsiveness to PD-1/PD-L1 mAb therapy is greater in patients with expression of PD-L1 in the tumour microenvironment. However, robust responses have also been observed in patients with low or absent expression of PD-L1. Using multiplex immuno-fluorescent labelling we sought to determine how infiltration of tumours by CD8+ T-cells, their expression of PD-1, and the expression of PD-L1 on both tumours and CD68 cells (macrophages) correlated with HPV status and outcome in a cohort of 124 oropharyngeal squamous cell carcinomas (OPSCC).
Keywords:
PD-L1; checkpoint inhibitor; human papillomavirus; oropharyngeal squamous cell carcinomas; tumour infiltrating lymphocytes.
MeSH terms
-
Antigens, CD / metabolism*
-
Antigens, Differentiation, Myelomonocytic / metabolism*
-
B7-H1 Antigen / metabolism*
-
Biomarkers, Tumor / metabolism
-
CD8-Positive T-Lymphocytes / immunology*
-
CD8-Positive T-Lymphocytes / metabolism
-
Carcinoma, Squamous Cell / immunology*
-
Carcinoma, Squamous Cell / metabolism
-
Carcinoma, Squamous Cell / virology
-
Female
-
Follow-Up Studies
-
Humans
-
Immunoenzyme Techniques
-
Lymphocytes, Tumor-Infiltrating / immunology*
-
Lymphocytes, Tumor-Infiltrating / metabolism
-
Macrophages / immunology*
-
Macrophages / metabolism
-
Macrophages / virology
-
Male
-
Middle Aged
-
Neoplasm Grading
-
Neoplasm Staging
-
Oropharyngeal Neoplasms / immunology*
-
Oropharyngeal Neoplasms / metabolism
-
Oropharyngeal Neoplasms / virology
-
Papillomaviridae / physiology*
-
Prognosis
-
Programmed Cell Death 1 Receptor / metabolism
-
Retrospective Studies
-
Survival Rate
-
Tumor Microenvironment
Substances
-
Antigens, CD
-
Antigens, Differentiation, Myelomonocytic
-
B7-H1 Antigen
-
Biomarkers, Tumor
-
CD68 antigen, human
-
Programmed Cell Death 1 Receptor